Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Takuya AdachiKazuhiro NousoKoji MiyaharaAtsushi OyamaNozomu WadaChihiro DohiYasuto TakeuchiTetsuya YasunakaHideki OnishiFusao IkedaShinichiro NakamuraHidenori ShirahaAkinobu TakakiHiroyuki TakabatakeShin-Ichi FujiokaHaruhiko KobashiYoshitaka TakumaShouta IwadouShuji UematsuKoichi TakaguchiHiroaki HagiharaHiroyuki Okadanull nullPublished in: Journal of gastroenterology and hepatology (2018)
Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.
Keyphrases